Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R)) ELEMENT--[Back to the Newsroom]# Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))New sublingual delivery system designed to provide more rapid relief from nausea caused by cancer medicinesOndansetron, currently sold under the brand name Zofran®, was the 53rd most commonly prescribed med ...